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Ocular Manifestation in Epstein 
Barr Virus Infection
Andi Arus Victor
Abstract
The Epstein-Barr Virus (EBV), a member of the Herpesvirus family, occurs 
commonly and infects more than 90% of people worldwide. Most of systemic 
EBV infections throughout childhood and adulthood are typically asymptomatic 
or paucisymptomatic. Even though ocular involvements in EBV infections are 
infrequently reported, an increasing number of ocular manifestations have been 
previously reported . Ocular manifestation caused by EBV infection involved 
all segments of the eye, including oculoglandular syndrome, dry eye syndrome, 
dacryoadenitis, conjunctivitis, episcleritis, keratitis, uveitis, choroiditis, retinitis, 
retinal vasculitis, and papillitis. Previous reports found neurologic complications 
such as papilledema, optic neuritis, ophthalmoplegia, impaired accommodation, 
and facial nerve palsy. Any atypical ocular inflammatory process should be con-
sidered EBV infection in the differential diagnosis. The ocular manifestations of 
systemic EBV infection are varied and have not been emphasized. And the role of 
EBV infection in ocular manifestation should be fully described.
Keywords: Epstein-Barr virus, oculoglandular syndrome, dry eye syndrome, 
dacryoadenitis, conjunctivitis, episcleritis, keratitis, uveitis, choroiditis, retinitis, 
retinal vasculitis, papillitis, papilledema, optic neuritis, ophthalmoplegia, impaired 
accommodation, facial nerve palsy
1. Introduction
The Epstein-Barr Virus (EBV) was first introduced in 1964 by Epstein, 
Anchong, and Barr [1–3], from a tissue sample of Burkitt’s lymphoma and was 
observed with an electron microscope. EBV has the same characteristic as herpes 
viruses in tissue cultures from specimens of Burkitt’s lymphoma. EBV is included 
in the family of Herpesviridae, which has a characteristic of the viral genome covered 
inside a nucleocapsid bounded by the viral envelope. In 1968, 4 years right after its 
first discovery, EBV was found to be the causal agent of the infectious mononucleosis 
(also called glandular fever). On other studies that conducted after, EBV was 
also found on tissue samples of nasopharyngeal carcinoma [3, 4], non-Hodgkin’s 
lymphoma, T-cell lymphoma, as well as oral hairy leukoplakia that associated with 
Acquired Immunodeficiency Syndrome (AIDS) [4, 5].
EBV DNA has a nature of double-strand and consists of guanosine and cytosine 
as much as 58%. Due to the nature of the receptors on B-cell surfaces, EBV shows a 
great permissivity toward B lymphocytes. When B lymphocytes are infected by EBV, 
they will be “transformed” into lymphoblasts in vitro, this process known as immor-
talization. EBV occurs commonly and infects approximately 90% of human [1–3]. 
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EBV-specific antibodies are found in about 95% of adults and 50–85% of the children 
[4, 5]. EBV infections are typically asymptomatic or have a subclinical infection, but 
once infected, it can lead to a viral carrier state for a lifetime. In some cases, primary 
EBV infection occurring during early adulthood could show clinical significance 
that is known as glandular fever or infectious mononucleosis [2, 5, 6]. Fortunately, 
most patients with infectious mononucleosis show a short recovery period since both 
cellular and humoral immune responses play a prominent role during the infection.
Ocular manifestations caused by EBV infection have been previously described. 
Previous studies showed that specific antibodies were detectable in 65% of tear and 
87.5% of serum samples from 40 normal subjects [4]. EBV infection manifested in 
the eye may involves all segments of the eye, including oculoglandular syndrome, 
dry eye syndrome, dacryoadenitis, conjunctivitis, episcleritis, keratitis, uveitis, 
choroiditis, retinitis, retinal vasculitis, and papillitis [3]. Follicular conjunctivitis 
is the most common ocular disease during acute EBV infection. It is observed in 
1–38% of cases and is usually unilateral. Bilateral stromal keratitis with coin-shaped 
lesions noted on tapering of systemic steroid therapy has been reported [6]. Uveitis 
occurred in 0.5% of patients with EBV infection [6].
The ocular manifestations of systemic EBV infection are numerous and have 
not been emphasized. Therefore, the role of EBV infection in ocular manifestation 
should be fully understood.
2. Pathophysiology infection of EBV
Usually, the first introduction to EBV in the period of childhood will cause 
subclinical infection, however if this primary event happens during adolescence, 
most of the time would trigger infectious mononucleosis. This syndrome consists in 
an acute and self-limiting lymphoproliferation of infected B cells and, at the same 
time, the development of virus-specific T cells that are triggered in order to tackle 
viral dissemination.
EBV transmission occurs by the sharing of saliva and then cause infection of 
mucosal surfaces and lymphoid tissues [3]. Almost most of seropositive individuals  
shed virus in their saliva. It was proposed earlier that initial replication of the 
virus happened also in the epithelial cells of the oropharynx, which causes the B 
cell infection by the previously infected epithelial cells. However, newer studies 
suggest that B cells located in the oropharynx could be infected first and act as the 
primary site.
During the latent stage of the infection, the site in which EBV persists within 
the body is the resting memory B cells. The viral replication in the oropharynx is 
partially suppressed in patients taking acyclovir, in the other hand, the amount of B 
cell EBV infected in the circulation remains the same.
Typical symptoms and signs are fever, pharyngitis, lymphadenopathy, and 
splenomegaly. The basic lesion is a perivascular infiltration of both normal and 
abnormal lymphocytes in all the tissues except bone marrow [7].
These cells are metaplastic noninvasive and to be formed in situ from other cells 
of the reticuloendothelial system. This lesion distributed throughout the body, and 
in any individual patient may be most marked in the central nervous system, liver, 
lungs, and other organs or systems.
Before the entry process into B cell, gp350, a major envelope glycoprotein, fixes 
to the receptor of the virus, CD21 molecule, which is located on the surface of the B 
cell. There are other factors besides CD21 that play a significant role, such as major 
histocompatibility complex (MHC) class II molecules that acts as a cofactor during 
B cells infection. EBV genome linear DNA molecules encode 100 viral proteins. 
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These proteins are significant in the process of construction of virion as well as 
carrying forward immune responses of the host.
EBV infection in vivo of the epithelial cells consequences in active replication 
while simultaneously with lysis of the cells as well as production of virus. Meanwhile, 
EBV infected B cells in vitro will become immortalized and causes latent infection. 
Only a small portion of cases that viral replication is triggered immediately after the 
infection of B cells.
Both cellular and humoral immunity plays an important role in the infection of 
EBV in humans. Even though the presentation of antibodies designed against viral 
structural proteins is critical, cellular immunity plays a higher role on the controller 
of EBV infection. The control of proliferation of EBV infected B cells in the primary 
infection is carried forward by CD4+, CD8+, and natural killer cells. During the 
period of infectious mononucleosis, a proportion of 40% of CD8+ T cells are focused 
on single replicative EBV protein sequence, meanwhile only 2% are focused to single 
latent EBV protein sequence.
During acute infection, first IgM and then IgG antibodies to viral capsid antigens 
(VCA) appear. Anti-VCA IgG may lead to virus carrier state and persist for a lifetime 
[3, 7]. Antibodies to early antigens rise during the acute phases of the disease and 
subsequently decrease to low or undetectable.
EBV can exist regardless of competent responses from the healthy immune system 
that are targeted toward it. It would most probably suggest that EBV has developed 
some tactics to evade the response from the immune system. EBV encrypts a cytokine 
as well as cytokine receptors that have a crucial role in moderating capable immune 
system therefore this allows tenacious infection. The 70% of amino acid sequence of 
EBV BCRF1 has the same characteristics as interleukin-10.
The protein of BCRF1 imitates the behavior of interleukin-10 of inhibits 
interferon-γ synthesis by in vitro human peripheral-blood mononuclear. In addi-
tion to that, EBV BARF1 protein acts as a soluble receptor for colony-stimulating 
factor 1. It is known that colony- stimulating factor 1 usually upregulates the 
expression of interferon-α of monocytes, therefore BARF1 protein able to operate 
as a decoy receptor to halt the action of cytokine. Since inhibition of the outgrowth 
of EBV infected cells in vitro is done by interferon-γ and interferon-α, BARF1 
and BCRF1 proteins could aid the EBV to avoid the immune system of the host in 
the period of both acute as well as latent infection. EBV also codes more than two 
proteins that cause apoptosis inhibition. Protein of the EBV BHFR1 is similar to 
the protein of human bcl-2 protein, this protein has the same function on blocking 
apoptosis. In addition, EBV LMP-1 increases several cellular protein expressions 
that hinders the process of apoptosis, i.e. bcl-2.
Antibodies to EBV nuclear antigens appear weeks to months later, providing 
serologic evidence of past infection. Lesions of the special sense organs are some-
what rare, but there are few reports of eye lesions or manifestations [7].
Ocular manifestations have been reported to affect all segments of the eye and 
most commonly associated with acute mononucleosis [3]. Manifestations in the 
ocular may be the cause of direct involvement of the eye and its adnexa through 
inflammatory syndrome similar to that of infectious mononucleosis, and those 
affecting vision and the neuro-ophthalmologic apparatus owing to a more remote 
occurrence of the lesion, most commonly involving the central nervous system [7].
3. Clinical manifestation
Ocular manifestations of acute EBV infection may affect the central nervous 
system to the extent of disturbance in the visual or oculomotor pathways, in 
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addition it could as well cause a disorder in the eye and adnexa of the eye [4, 8]. 
Further manifestations were observed due to the advancement of diagnostic tools 
that could give much more sensitive and specific results [8].
Neurologic abnormalities caused by EBV could disturb the vision of its host. 
Disorders that have been reported previously consisted of papilledema, conver-
gence deficiency, nerve palsies, retinal necrosis, central nervous system vasculitis, 
retinochoroiditis, necrotizing retinitis with extensive hemorrhage that were 
co-infected with human immunodeficiency virus and cytomegalovirus and optic 
neuritis.
The appearance of yellowish, coalescing lesion in the macula as well as 
edematous optic disk were seen in a patient with EBV infection by Kim et al. [9]. 
From our previous case-report, it was examined from funduscopy a peculiar 
finding of prominent presentation of white sheathing retinal phlebitis covering 
all four retinal quadrants (Figure 1). Other reports had described this finding as 
frosted branch angiitis. It was also well known that frosted branch angiitis has 
been seen regularly in numerous disorders such as Crohn disease, Behcet dis-
ease, and systemic lupus erythematosus. However, from our previous case, the 
patient did not show any typical symptoms of Crohn disease, Behcet disease, and 
systemic lupus erythematosus, also, PCR was done on the patient’s serum and 
was positive for EBV.
EBV infects lymphoid tissues and also mucosal surfaces. In the cellular level, 
EBV infects B cell and conforming virus-specific T cells, which will lead to symp-
toms such as lymphadenopathy and pharyngitis. Based on seroepidemiologic data, 
it was reported that EBV infects all parts of the eye, though the most common 
abnormality includes follicular conjunctivitis. After the availability of virus-specific 
tests, other disorders of the anterior segment that is associated with EBV were 
detected more frequently, which includes keratitis, iritis, episcleritis, as well as 
dacryoadenitis.
It was found by Plugfelder et al., [10], that some cases of primary Sjogren’s 
syndrome developed right after infectious mononucleosis. These authors [10] 
gathered patients that have aqueous tear deficiency and evaluated them for a 
serologic finding of EBV infection. A significant correlation was found between 
elevated EBV titers and severe aqueous tear deficiency once the results were placed 
in multivariate analysis. This suggests that EBV infection could be a risk factor in 
developing aqueous tear deficiency [10, 11].
Inflammation of the conjunctiva has been seen and linked with keratitis, that 
variate from mild hyperemia to mild follicular reaction in the inferior and superior 
Figure 1. 
Bilateral fundus photographs showing white sheathing of retinal veins in four retinal quadrants (frosted 
branch-like appearance) with macular edema. Reprinted from [1]. Copyright 2016 by Retinal Cases & Brief 
Reports.
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tarsal conjunctiva. A study by Matoba [4] has found stromal keratitis related to EBV 
infection to infect all layers of stroma. Matoba [4] has also reported there were two 
forms of EBV-related keratitis, the first type was a granular, multiple, well-defined, 
ring, or circular-shaped opacities which was distributed all over the anterior as well 
as mid-stroma. Another form is nonsuppurative, multifocal keratitis including deep 
layers or full thickness of peripheral cornea and also related to various grades of 
vascularization [4]. In another study by Chodosh J, stromal keratitis associated with 
EBV infection presented three principal forms (Figure 2) [7].
Type I: multifocal subepithelial infiltrates that resemble adenoviral keratitis.
Type II: multifocal, blotchy, pleomorphic infiltrates with active inflammation or 
granular ring-shaped opacities (inactive form) in anterior to midstroma.
Type III: multifocal deep or full thickness peripheral infiltrates, with or without 
vascularization.
Matoba et al. [4] proposed a hypothesis about the pathophysiology of EBV 
related keratitis onset being carried forward by infectious and immunologic 
processes. Due to the quick response to the introduction of topical corticosteroid 
and seeming resolution of the inflammation without involving the use of antiviral 
therapy, it is more likely that immunologic processes were involved rather than viral 
replication. If this is true, the cornea was affected could be due to native keratocyte 
share a similar antigen with EBV, or it might be caused by EBV antigen develops 
located within the tissue [4].
Other common symptoms affecting the ocular include periorbital edema, pain 
when rotating the eyes, deep orbital pain, photophobia, as well as headache. It was 
spotted by Tanner [8] that episcleritis, as well as uveitis as part of the ocular mani-
festation of EBV infection. Tanner [8] reported nongranulomatous uveitis taking 
place at the end stage of clinical manifestation of infectious mononucleosis had 
been noted in four cases. One specific exhibition is the disorder of the oculomotor 
apparatus. Fledelius et al. [8] observed an exclusive inferior rectus paresis. Motto 
and Ashworth [8] were the first to notice a bilateral papilledema case of infectious 
mononucleosis with the nonappearance clinical manifestation of encephalitis nor 
meningitis. Other studies observed ptosis, nystagmus, as well as diplopia in their 
patients [8].
4. A diagnostic approach for detecting ocular disease by EBV infection
Most of the ocular manifestations linked to the EBV infection have been based 
mostly on seroepidemiologic data. This claimed is supported by the fact that 
Figure 2. 
Subepithelial infiltrates resembling adenoviral infection-associated keratitis in a patient with recent primary 
EBV infection. Reprinted from [2]. Copyright 1990 by Surv Ophthalmol.
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numerous patients with EBV infection that showed ocular manifestations have been 
confirmed from in-situ hybridization of EBV genome from the biopsy of suspected 
tissue specimens.
The diagnosis of EBV infection by serologically for quite sometimes has been 
hinge on heterophil antibodies detection [4]. Heterophile antibodies are classified 
in the IgM group and would typically reach its highest levels around the second to 
third week since the first onset of the sickness and would exist and visible till 1 year 
[4]. They are detectable in up to 90% of adults who suffered from primary EBV 
infection [4].
Monospot test is a test that could be used in detecting EBV infection. This test is 
a quick slide agglutination test for specific heterophile antibodies produced by the 
human immune system in response to EBV infection. The sample will clump when 
it exposes to equine erythrocytes if these specific antibodies present in the patient’s 
blood specimen. The Monospot test is considered to be a very specific test. However, 
its sensitivity falls in the range of 70–90% [12]. Patients with atypical clinical 
features and patients and with suspected of chronic infection are better evaluated 
with EBV specific serologic test that measure antibody levels against VCA, EBNA, 
and EA [4].
5. Management
The overall goal of EBV treatment is mainly supportive since the disease is 
usually self- limited [4]. Antiviral drugs have been used to inhibit the replication 
cycle of the virus. The action of antiviral agents can be divided into: (1) disrupting 
with cellular process which the virus uses for its replication; (2) inhibits the func-
tion of the virus by bind to the nucleic acid; (3) modifies the viral envelope which 
is resulting in preventing the virus infecting new cells; (4) inhibits the formation 
of new progeny by interfering with viral assembly; (5) interferes with the viral 
enzyme and inhibits their function; (6) prevents the processing of viral precursor 
polypeptide. The effect of some of the antiviral agents used in EBV infection is 
uncertain, but some studies have reported good results of treating EBV infection 
with systemic antiviral [4, 11].
Several antiviral drugs have been used to treat EBV infection and can be grouped 
into three as nucleoside analogs such as ganciclovir, valganciclovir, acyclovir, 
valaciclovir, acyclic nucleotide analog such as cidofovir and adefovir, and pyrophos-
phate analog such as foscarnet [11]. Acyclovir is recommended as the first-line drug 
for treating EBV infection. Therefore, it has become the most commonly prescribed 
antiviral regimen [13–15]. Anderson et al. [13] have found a significant reduction 
of EBV-infected B-lymphocytes after acyclovir treatment. Accordingly, systemic 
acyclovir therapy showed a good result of treating EBV-associated ocular involve-
ment and ARN [14].
Acyclovir triphosphate inhibits viral replication by acting as a competitive 
substrate for viral DNA polymerase, and its subsequent incorporation into the viral 
DNA chain results in obligate chain termination. The recommended regime is intra-
venous acyclovir 10 mg/kg every 8 hours (or 1500 mg/m2) per day for 5–10 days, 
followed by oral acyclovir 400–800 mg 5 times daily for an additional 6–12 weeks. 
Second eye involvement may occur within the first 6 weeks after EBV infection; 
thus, the minimum duration of subsequent oral therapy was 6 weeks. Even though 
some ophthalmic centers are switching to oral therapy alone, few studies found a 
higher level of intravitreal acyclovir when given intravenously [14–16]. From the 
limited data available, one may conclude that acyclovir given intravenously and 
orally is the recommended regime [15, 16].
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The effectiveness of steroid along with antiviral drug in treating ocular manifes-
tations of EBV infection remains unclear. Some studies described that ophthalmic 
steroids relieve the symptoms of ocular inflammation in the anterior segment of 
the eye, including keratitis, anterior uveitis, and ocular allergies or injuries, yet its 
effect on the posterior part is still not clear [2, 4, 16].
6. Conclusion
It can be concluded that distinctive characteristic pathologic clinical manifesta-
tion, as well as lesions of infectious mononucleosis, exists in the ocular. The ocular 
manifestations of systemic EBV infection are wide-ranging and have not been high-
lighted. EBV infection is best diagnosed using heterophile antibody tests to detect 
primary EBV infections and serology tests for asymptomatic patients. Despite of the 
self-limiting nature of the disease, acyclovir still becomes the first line of treatment 
with its attribute to reduce the viral replication. EBV infection should be included in 
the differential diagnosis of most unusual inflammatory course of the eye.
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